As president of Covidien’s Vascular Therapies division, Stacy Enxing Seng was responsible for managing a global organization of approximately 4,000 employees with $1.6 billion in revenue. She joined Covidien in July 2010 through the ev3 acquisition where she was a founding member and executive officer responsible for leading ev3’s peripheral vascular division from inception to a $350 million business. As and Executive in Residence at the company, Enxing Seng oversees the company’s 2020 vision, as well the Fire1 incubator.